Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

effacer Trouvé 206 recommandations pour 39 médicaments et 0 équivalent thérapeutique
Les recommandations supprimées et les demandes rejetées sont affichées. Les cacher.
8.2.1. Cytotoxic medicines
  1. Arsenic trioxide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  2. Asparaginase Informations générales
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified
  3. Azacitidine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Myeloid leukaemia
  4. Bendamustine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  6. Calcium folinate (leucovorin calcium) Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 15 mg tablet
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon Burkitt lymphoma including Burkitt leukaemia Malignant neoplasm metastasis in large intestine
  8. Carboplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
    Indications
    Other specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Malignant neoplasms of cervix uteri
  10. Cisplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
    • Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Malignant neoplasms of cervix uteri
  11. Cladribine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
    Indications
    Langerhans cell histiocytosis
  12. Cyclophosphamide Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 25 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Rhabdomyosarcoma primary site Hodgkin lymphoma Plasma cell myeloma Other specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  14. Dacarbazine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  16. Daunorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Myeloid leukaemia
  18. Doxorubicin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Malignant neoplasms of breast Hodgkin lymphoma Plasma cell myeloma Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified
  19. Doxorubicin (as pegylated liposomal) Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  20. Etoposide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
    • Oral > Solid: 100 mg capsule
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Ewing sarcoma of bone and articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Burkitt lymphoma including Burkitt leukaemia
  21. Fludarabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  23. Gemcitabine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  24. Hydroxycarbamide (hydroxyurea) Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
  25. Ifosfamide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Burkitt lymphoma including Burkitt leukaemia
  26. Irinotecan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  27. Melphalan Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  30. Oxaliplatin Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  32. Pegaspargase Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  33. Procarbazine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma
  34. Realgar-indigo naturalis formulation Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  35. Temozolomide Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    • Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg
    Indications
    Ewing sarcoma of bone and articular cartilage of unspecified sites Other specified gliomas of brain Unspecified malignant neoplasms of ill-defined or unspecified sites Neuroblastoma, NOS
  36. Tioguanine Informations générales
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  38. Vincristine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Retinoblastoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Langerhans cell histiocytosis Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphoma, not otherwise specified
  39. Vinorelbine Informations générales
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site